Insider Selling: Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Sells $22,100.00 in Stock

Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Songjiang Ma sold 2,000 shares of the stock in a transaction dated Tuesday, December 17th. The shares were sold at an average price of $11.05, for a total value of $22,100.00. Following the completion of the sale, the president now directly owns 2,940,467 shares of the company’s stock, valued at approximately $32,492,160.35. The trade was a 0.07 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Gyre Therapeutics Trading Up 4.5 %

Shares of GYRE stock opened at $11.14 on Friday. The business’s 50 day simple moving average is $12.86 and its 200 day simple moving average is $12.58. Gyre Therapeutics, Inc. has a one year low of $8.26 and a one year high of $30.40.

Institutional Investors Weigh In On Gyre Therapeutics

A number of institutional investors have recently modified their holdings of GYRE. Barclays PLC lifted its holdings in Gyre Therapeutics by 281.8% in the third quarter. Barclays PLC now owns 9,288 shares of the company’s stock valued at $116,000 after buying an additional 6,855 shares during the period. Geode Capital Management LLC grew its holdings in Gyre Therapeutics by 16.9% during the 3rd quarter. Geode Capital Management LLC now owns 303,647 shares of the company’s stock worth $3,808,000 after acquiring an additional 43,840 shares during the period. State Street Corp raised its position in shares of Gyre Therapeutics by 8.8% in the 3rd quarter. State Street Corp now owns 104,490 shares of the company’s stock worth $1,310,000 after acquiring an additional 8,412 shares in the last quarter. FMR LLC acquired a new position in shares of Gyre Therapeutics in the 3rd quarter valued at about $47,000. Finally, Advantage Alpha Capital Partners LP bought a new stake in shares of Gyre Therapeutics during the 3rd quarter valued at about $334,000. 23.99% of the stock is owned by institutional investors.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.